Shanghai Allist Valuation Multiples

Shanghai Allist Overview

About Shanghai Allist

Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment.

Founded

2004

HQ

Employees

N/A

Website

allist.com.cn

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $522M

EBITDA: $243M

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Shanghai Allist Financials

Shanghai Allist reported last fiscal year revenue of $522M and EBITDA of $243M.

In the same fiscal year, Shanghai Allist generated $501M in gross profit, $243M in EBITDA, and $210M in net income.

Shanghai Allist P&L

In the most recent fiscal year, Shanghai Allist reported revenue of $522M and EBITDA of $243M.

Shanghai Allist expects next 12-month revenue of XXX and NTM EBITDA of XXX

Shanghai Allist Stock Performance

Shanghai Allist has current market cap of $6B, and enterprise value of $6B.

Shanghai Allist's stock price is $14.31.

Shanghai Allist Valuation Multiples

Shanghai Allist trades at 11.4x EV/Revenue multiple, and 24.5x EV/EBITDA.

Shanghai Allist Financial Valuation Multiples

As of April 18, 2026, Shanghai Allist has market cap of $6B and EV of $6B.

Equity research analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shanghai Allist has a P/E ratio of 30.7x.

Shanghai Allist Margins & Growth Rates

Shanghai Allist's revenue in the last fiscal year grew by 76%.

Shanghai Allist Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Shanghai Allist M&A Activity

Shanghai Allist acquired XXX companies to date.

Last acquisition by Shanghai Allist was on XXXXXXXX, XXXXX. Shanghai Allist acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Shanghai Allist Investment Activity

Shanghai Allist invested in XXX companies to date.

Shanghai Allist made its latest investment on XXXXXXXX, XXXXX. Shanghai Allist invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).